Chronic kidney disease (CKD) is a leading cause of mortality and morbidity around the world. The prevalence of CKD increases steadily over the past decade in parallel to the rapid expansion of diabetic population. Apart from increased mortality, CKD also has significant impact on quality of life and the economy. The approach to deal with the global CKD epidemic is multifaceted. Early detection by screening high-risk individuals such as those with hypertension and diabetes is important and cost-effective. However, low CKD awareness in many countries may impose barriers to early intervention. Hence raising CKD awareness among public and policy makers should be encouraged. In addition, the use of peritoneal dialysis, a less costly and home-based dialysis modality compared with in-center haemodialysis, should be promoted to maximize access to dialysis with limited resources. Finally, ongoing research and clinical trials through international collaborations could provide further insight into the pathophysiology of CKD progression, and establish the foundation for development of specific therapeutic agents to retard progression to end stage renal failure.
SUMMARY AT A GLANCE
Facing the global healthcare challenges posed by chronic kidney disease (CKD), this review outlines multiple practical strategies to tackle the CKD epidemic.
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Non-communicable diseases are the major cause of the death around the world. In 2016, chronic kidney disease (CKD) caused 1.19 million deaths globally, which has increased by 28.8% from 2006.
1 This made CKD the 11th leading cause of death in 2016, compared with 13th and 27th in 2013 and 1990, respectively. 1 Moreover, the global prevalence of CKD is estimated to be 11-13%, 2 and this number is likely to rise further with the aging population and the increasing prevalence of diabetes. As a result, the global burden of CKD becomes a major public health problem in many countries. Herein, we review the changing epidemiology of CKD, impact of CKD on patient survival and the economy, and most importantly, we discuss the potential solutions to deal with the emerging CKD epidemic.
THE CHANGING EPIDEMIOLOGY OF CKD IN THE WORLD
The causes of CKD vary between countries, ethnicities and age. Diabetic nephropathy is the most common renal disease leading to renal replacement therapy (RRT) in the United States (44%) 3 and the United Kingdom (27.5%). 4 In contrast, primary glomerulonephritis is the major cause of end stage renal disease (ESRD) in China. 5 However, approximately 10-15% of patients who reached ESRD did not have a specific renal diagnosis. 3, 4 Although immunoglobulin A nephropathy (IgAN) used to be the most frequent glomerulonephritis around the world (including Italy, Spain, Denmark and Japan), 6 it is important to note that the spectrum of glomerular diseases changed significantly with time. In south eastern United States, there was a substantial increase in frequency of diabetic glomerulosclerosis from 5.5% to 19.1% over the past three decades, compared to a relatively stable prevalence of IgAN (from 10.2% to 9.4%) and a declining rate of membranous nephropathy (from 17.8% to 10.6%) in the contemporary period. 7 Similarly, our group retrospectively analysed the the second most common cause of nephrotic-range of proteinuria in patients aged ≥46 years. 8 This rising prevalence of diabetic nephropathy occurs in parallel to the expanding diabetic population, in spite of the increased use of glucoselowering medications and renin-angiotensin-aldosterone system inhibitors. 9 Therefore, it is logical to hypothesize that the present global burden of CKD is largely driven by the epidemic of diabetes and diabetic kidney disease. Not only is CKD associated with mortality, it also leads to significant morbidity and disability. In a cross-sectional survey in the United States, the prevalence of self-reported difficulty in activities of daily living was significantly higher in patients with CKD compared with those without, after adjustment of age and gender. 11 In addition, CKD frequently coexists with other chronic illnesses such as diabetes, hypertension and cardiovascular diseases, which may further limit the functional capacities of individuals. In the latest update from the Global Burden of Disease Study, the total disabilityadjusted life years of CKD increased significantly from 29.2 thousand to 35.0 thousand in the past decade, which outnumbered many neurological disorders including dementia and Parkinson's disease, as well as chronic liver diseases. 12 Notably, CKD is also associated with substantial healthcare cost. In a nationwide registry in Sweden, the annual health-care cost was 4-fold higher in non-dialysis CKD patients, and up to 45 times higher in patients on haemodialysis (HD), when compared with general population. 13 
GLOBAL IMPACT OF CKD

HOW TO DEAL WITH THE CKD EPIDEMIC?
Raising public awareness, early detection and timely referral
Patients with CKD may be completely asymptomatic before they have significant loss of renal function. Moreover, diagnosis of CKD relies on laboratory tests including blood test (for serum creatinine or cystatin C in order to estimate glomerular filtration rate (GFR)) and urinalysis (for urinary sediments especially albuminuria), which probably are less readily available than sphygmomanometer and glucometer in the diagnosis of hypertension and diabetes. This may explain the lack of awareness of CKD around the world. A large random population survey in Canada revealed an alarmingly low awareness of CKD: only 8% of CKD patients knew their diagnosis.
14 Of note is that elderly and women were more likely to be unaware of CKD. 14 Moreover, limited access to healthcare in low-income and middle-income countries may further exacerbate this problem. The overall CKD awareness among general population and even high cardiovascular risk groups across 12 low-income and middle-income countries was less than 10%. 15 In Hong Kong, we found that less than half of citizens were aware that hypertension and diabetes, the major causes of ESRD, could damage kidney function. 16 A structured public health education programme is required to fill the knowledge gap of risk factors for CKD, as well as to promote CKD awareness in the public. Given its asymptomatic nature, screening of CKD plays an important role in early detection. In this regard, the Hong Kong Society of Nephrology has spent a great effort to conduct relevant population-based studies. The Screening for Hong Kong Asymptomatic Renal population and Evaluation programme in 2003 aimed at identifying the prevalence of unrecognized renal disease in asymptomatic individuals. 17 Among 1201 asymptomatic participants, 17.4% had abnormalities in urine dipstick (defined as presence of protein, blood or glucose). In addition, 33.2% of participants older than 60 years had hypertension and/or abnormal urinalysis. Later, we extended our screening programme to individuals with family history of ESRD, an increasingly recognized risk factor for CKD. The Relatives In Silent Kidney disease Screening study revealed that 23.1%, 25.9% and 4.4% of 844 asymptomatic first-degree relatives of CKD patients had proteinuria, haematuria and glycosuria, respectively. 18 In contrary to previous beliefs, the presence of proteinuria and glycosuria in participants did not correlate to the stages of CKD of their relatives, suggesting that first-degree relatives of patients in all stages of CKD were at risk of CKD. 18 In order to implement an effective screening strategy, the Asian Forum for Chronic Kidney Disease Initiatives published a positional statement for early detection of CKD. 19 In essence, individuals older than 65 years, patients with diabetes, hypertension, family history of CKD or potentially receives nephrotoxic drugs, should be screened. 19 From an economic perspective, screening CKD by detection of proteinuria was shown to be cost-effective in patients with hypertension or diabetes in a systematic review. 20 Referral to nephrologist is essential in the management of CKD. A recent Cochrane review reported that early referral to specialist care (defined as more than 1-6 months before initiation of dialysis) was associated with 44% reduction in 5-year mortality and a shorter hospital stay by 9 days. 21 Patients who were referred early were more likely to start with peritoneal dialysis (PD), and if not, they were less likely to receive temporary venous catheters insertion upon initiation of HD. 21 
Advance in treatment
Over the past decades, there has been major advancement in the pharmacological treatment in CKD in order to slow down the progression to ESRD. Some important landmark studies are highlighted below.
Guideline published by the Kidney Disease: Improving Global Outcomes work group provides a comprehensive overview of management of glomerulonephritis.
22 Supportive therapy including blood pressure control and blockade of renin angiotensin system remains the cornerstone in the treatment of IgAN. 22, 23 Although earlier evidence supported the use of steroid in patients with persistent proteinuria, the recently published Supportive versus immunosuppressive Therapy Of Progressive IgA Nephropathy trial questioned the benefit of immunosuppressant in addition to optimal supportive treatment. 24 This randomized controlled trial showed that larger proportion (17% vs 5%) of patients achieved full clinical remission (protein-to-creatinine ratio of <0.2 g and a decrease in the estimated GFR of <5 mL/min) after receiving immunosuppressant on top of supportive therapy. Nevertheless, this result did not translate into a difference in annual decline in estimated GFR between the two groups after 3 years. 24 On the other hand, targeted-release budesonide, which worked by modulating local intestinal immune response and minimizing systemic absorption by first-pass effect, showed promising results in a phase 2b trial. 25 By further reducing mean urine protein-tocreatinine ratio by 24.4% after adequate renin-angiotensin system blockade, budesonide may become a new option to delay progression of IgAN.
25
Novel anti-diabetic agents, namely sodium-glucose cotransporter 2 inhibitors and glucagon-like pepetide-1 agonists, may extend their benefits beyond glycaemic control to an improvement in renal and cardiovascular outcomes. In patients with type 2 diabetes and high cardiovascular risk, empagliflozin significantly reduced the risk of incident or worsening nephropathy by 38%, and initiation of RRT by 55%, when compared with placebo. 26 These together translated to an approximate 1.5 mL/min less decline in annual GFR. 26 Similar finding was reported by another trial which studied canagliflozin, another sodium-glucose cotransporter 2 inhibitor. Canaglifozin significantly decreased the composite of 3-point major adverse cardiovascular events by 14%. 27 In addition, the renal composite endpoint including a sustained 40% reduction in the estimated GFR, the need for RRT, or death from renal cause, was reduced by 40%. 27 On the other hand, liraglutide, a subcutaneous glucagon-like pepetide-1 agonist given once daily, was associated with 14% reduction in microvascular composite endpoint, which was mainly driven by new onset macroalbuminuira. 28 However, the mechanism responsible for the renoprotective effect of these novel agents is not completely understood and is probably independent of the glycaemic control. Further studies are warranted to elucidate the underlying pathophysiology. Despite the discovery of novel therapeutic options, not all patients with CKD received optimal control of risk factors. 29 This programme aimed at providing comprehensive management including annual blood test, and two yearly examination for retinopathy, neuropathy and nephropathy, for diabetic patients in primary care setting. 29 Stage 3 and 4 CKD patients who were co-managed by primary care providers and nephrologists received significantly more tests for progression and complications, in particular serum GFR and urine protein. 30 This illustrated the importance of collaboration between primary care providers and specialists in screening, monitoring of CKD and adequate control of associated risk factors.
Provision of cost-effective quality dialysis and palliative renal care
It is estimated that worldwide use of RRT will increase more than double to 5.4 million from 2010 to 2030, with the largest treatment gap in Asia and Africa. 31 This creates heavy economic burden in many countries. The relative cost ratio of HD to PD varies between developing and developed countries, ranging from 2.35 in Hong Kong to 1.1 in China, India and Malaysia. 32 Therefore, increasing PD utilization may help to reduce national health-care expenditure. Apart from economic benefit, PD may potentially lower infection risk, enhance patient satisfaction, and preserve residual renal function, while having a comparable survival rate with HD. 33 These advantages have led to an increase in PD use in many parts of the world, notably China, Thailand and United States, with a view to maximize the number of ESRD patients treated by dialysis with limited health-care resources. 34 Nevertheless, the success of 'PD-first programme' would require implementation of government policy that favours this modality, reduction of costs (e.g. local manufacture of PD solutions) and provision of training to nephrologists to acquire related technique and expertise. Home HD is another home-based therapy that will benefit patients. Both PD and Home HD, as home therapies, have been shown to provide more cost-effective, better outcome and quality of life than in-center HD programmes. 35 Is dialysis the only way out for ESRD patients? Palliative care is a frequently forgotten, or forgone, option. In fact, dialysis does not provide survival benefit in many frail, elderly patients with severe comorbidities, when compared with conservative treatment. 36 Many times, elderly patients may not have chance to discuss alternative therapy other than dialysis with nephrologists, and may have unrealistic expectation towards dialysis. 37 A multidisciplinary team that involves nephrologists, palliative care physicians, social workers and nurses is essential to address individuals' needs if one pursue for palliative care. Not only for initiation, appropriate timing for termination of dialysis is also important for those patients who gradually deteriorated with progressive worsening of general well-beings because of the severe comorbidities.
CONCLUSION
While CKD emerges to be a global health challenge, there is no simple solution to the CKD epidemic (Table 1) . CKD management should be multidisciplinary and the cooperation between nephrologists, general physicians, primary care providers and allied medical professionals is of utmost importance for screening asymptomatic individuals who are at risk of CKD, monitoring progression (estimated GFR and proteinuria), detecting cardiovascular complications, and timely referral to specialist care. In addition, continued medical research may identify specific biomarkers associated with CKD progression and thus lead to personalized treatments targeting the underlying pathophysiology. The policy makers should be informed of the enormous burden of CKD on the society and economy; at the same time, they should provide cost-effective dialysis and promote awareness of CKD through public education. Last but not least, international collaboration between national authorities to overcome these challenges could not be overemphasized. nephrologists to have coordinated care of CKD patients and also ensure timely referral before initiation of RRT 4. Continue medical research to elucidate the underlying pathophysiology of CKD progression and develop specific therapeutic agents 5. Provision of cost-effective dialysis by government • Utilization of home-based therapies like PD and home HD should be encouraged because it is in general less costly and have a better outcome and quality of life than in-centre-based HD 6. Referral to palliative care • Decision regarding initiation and/or termination of RRT should be individualized as RRT may not benefit elderly patients with severe comorbidities CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration; HT, hypertension; HD, haemodialysis; PD, peritoneal dialysis; RRT, renal replacement therapy.
